Clinical experience with linezolid: A case series of 53 patients

Infectious Diseases in Clinical Practice

Volumn 11, Issue 4, 2002, Pages 198-204

  Babcock, Hilary M ^a,b   Fraser, Victoria ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Campus Box 8051 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASCITES FLUID; BACTERIAL INFECTION; BACTERIUM CULTURE; BLOOD; BONE INFECTION; DIARRHEA; DRUG APPROVAL; DRUG ERUPTION; DRUG MONITORING; DRUG SCREENING; ENTEROCOCCUS FAECIUM; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PANCYTOPENIA; PRURITUS; TEACHING HOSPITAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036590097     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200205000-00003     Document Type: Article

References (20)

1. Swaney SM, Aoki H, Ganoza MC, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
2. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacotherapy 2001;35:566-75.
3. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27.
4. Birmingham M, Rayner C, Flavin S, et al. Treating patients with significant resistant gram-positive infections with linezolid. In: Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, September 7, 2000.
5. Birmingham M, Zimmer G, Hafkin B, et al. Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant gram-positive infections. In: Programs and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, November 11-18, 1999.
6. Birmingham M, Zimmer G, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant resistant gram-positive infections. In: Program and abstracts of the 39th Conference on Antimicrobial Agents & Chemotherapy, September 26, 1999.
7. Smith P, Birmingham M, Zimmer G, et al. Clinical outcomes, safety, and tolerance of linezolid for resistant gram-positive infections in patients with neutropenia. In: Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, November 18, 1999.
8. Leach T, Schaser R, Hempsall K, et al. Clinical efficacy of linezolid for infections caused by vancomycin-resistant enterococci in a compassionate use program. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, September 7, 2000.
9. Moise P, Birmingham M, Forrest A, et al. Linezolid use in patients who are intolerant to or fail vancomycin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17, 2000.
10. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multi drug-resistant gram-positive bacterial infections [see comments]. Clin Infect Dis 2000;30:146-51.
11. Antony SJ, Bitter KM, Moreland T, et al. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms. Clin Infect Dis 1999;29:1341-2.
12. Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689-90.
13. McNeil SA, Clark NM, Chandrasekar PH, et al. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis 2000;30:403-4.
14. Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus bacteremias [letter; comment]. Clin Infect Dis 2000;31:208-9.
15. Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-5.
16. Zeana C, Kubin CJ, Della-Latta P, et al. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature. Clin Infect Dis 2001;33:477-82.
17. Zurenko G, Todd WM, Hafkin B. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In: Program and abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 26, 1999.
18. Wilks N. Safety and tolerance of linezol in phase II trials. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999.
19. Bruss JB, Smith LG, Duvall SE, et al. Safety and tolerance of linezolid: Adverse events reported in phase III trials. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17, 2000.
20. Zyvox [Package Insert]. Kalamazoo, Michigan: Pharmacia & Upjohn, 2002.